| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| ImmunityBio Inc. | ANKTIVA - (ResQ201A-NSCLC) | Non-Small Cell Lung Cancer | BLA Filing | Trial Planned | Intravenous | Oncology |
| ImmunityBio Inc. | Anktiva (N-803) + various Checkpoint Inhibitors (QUILT-3.055) | NSCLC, Various tumors | Phase 2b | Data Released | Intravenous | Oncology |
| ImmunityBio Inc. | ANKTIVA | NMIBC Papillary Disease | BLA Filing | Ongoing | Intravenous | Oncology |
| ImmunityBio Inc. | t-haNK and Anktiva (N-803) - (QUILT-88) | Pancreatic cancer | Phase 2 | Intravenous | Oncology | |
| ImmunityBio Inc. | ANKTIVA (nogapendekin alfa inbakicept) - (QUILT-3.055) | 2L Non-Small Cell Lung Cancer(NSCLC) | Phase 3 | Ongoing | Intravesical | Oncology |
| ImmunityBio Inc. | Anktiva (N-803) and Cytokine-enriched natural killer (m-ceNK) cells | Acute myeloid leukemia (AML) | Phase 2 | Intravenous | Oncology | |
| ImmunityBio Inc. | ANKTIVA - (ResQ201A-NSCLC) | Non-Small Cell Lung Cancer | BLA Filing | Trial Planned | Intravenous | Oncology |
| ImmunityBio Inc. | Anktiva (N-803) Lung-MAP | Non-small cell lung cancer (NSCLC) | Phase 2/3 | Intravenous | Oncology |